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The	 retinal	 blood	 supply	 originates	 in	 the	 ophthalmic	 artery	 and	 branches	 into	 the	 different	
sections	 of	 the	 retina.	 	 The	 external	 retina,	 which	 contains	 the	 cell	 bodies	 of	 the	 photoreceptors,	 is	
provided	with	nutrients	by	the	choroid	blood	vessels.		The	inner	layer	and	ganglion	layer,	which	contains	
the	ganglion	bipolar	and	amacrine	cell	bodies,	 is	nourished	by	the	central	 retinal	artery	 (CRA)	 (Brown,	
1991).	
Complete	 retinal	 ischemia	 occurs	 when	 the	 opthalamic	 artery	 is	 occluded.	 	 Major	 causes	 of	
retinal	 ischemia	 are	 central	 retinal	 artery	 occlusion	 (CRAO),	 branch	 retinal	 artery	 occlusion	 (BRAO),	







and	 risk	 factors	 of	 CRAO	 but	 affects	more	 of	 a	 specific	 area	 of	 the	 inner	 retina	 depending	 on	which	
branch	is	occluded	(Brown,	1991).	
Venous	occlusive	diseases	are	more	common	clinically	than	arterial	occlusions.		The	risk	factors	
for	 CRVO	 are	 similar	 to	 those	 of	 CRAO	 but	 also	 include	 an	 elevated	 intraocular	 pressure	 (IOP)	 or	 an	




hydroxyl-5-methyl-4-isoxazole-propionate),	 and	 kainite	 receptors	 are	 ionotropic	 receptors	 in	 neurons	
that	are	activated	by	glutamate	which	is	a	main	neuron	neurotransmitter	(Digledine	et	al	1999).		NMDA	
receptors	are	 responsible	 for	 regulating	 the	 influx	of	calcium	and	other	 ions	 in	 the	cell.	 	Normally	 the	
channel	 is	 blocked	 by	Mg2+	 ions	 (Eby	 and	 Eby,	 2006).	 	 Under	 normal	 circumstances	 a	 nearby	 AMPA	












of	 activating	 an	 integral	 ion	 channel	 they	 activate	 secondary	 messengers	 usually	 G-proteins,	 which	
activate	 ion	 channels	 on	 the	 plasma	 membrane.	 	 To	 date	 eight	 distinct	 subtypes	 of	 metabotropic	
glutamate	receptors	(mGluRs)	have	been	identified	and	separated	into	three	groups	based	on	function	
and	 sequence	 homology	 (Thoreson	 and	Witkovsky,	 1999).	 	 Group	 1	mGluRs	 (mGlu1	 and	mGlu5)	 are	
usually	 located	postsynaptically	and	enhance	the	cell’s	excitability	by	mobilizing	 intracellular	Ca2+	and	
activating	protein	kinase	C,	which	leads	to	several	signal	transduction	pathways.	
Group	 II	 (mGlu2	 and	 mGlu3)	 and	 Group	 III	 (mGlu4	 and	 mGlu6-8)	 are	 typically	 found	
presynaptically.		The	transduction	process	of	these	receptors	involve	a	negative	coupling	with	adenylate	




the	 cascade	 comes	 from	 the	 lack	 of	 oxygen	 and	 glucose	 supply.	 	 This	 leads	 to	 decreased	 rates	 of	
glycolysis	and	oxidative	phosphorylation,	which	causes	levels	of	ATP	to	fall	(Lipton,	1999).		
The	main	 impact	 of	 the	decrease	of	ATP	 in	 the	neuron	 is	 the	 inhibition	of	 the	Na⁺/K⁺-ATPase	
transporter,	which	is	a	transporting	enzyme	on	the	cell	membrane.	The	main	function	of	this	enzyme	is	
to	restore	the	resting	potential	of	the	neuron	after	it	has	been	hyperpolarized	from	the	release	of	excess	
potassium.	 	When	 the	 neuron	 becomes	 hyperpolarized	 the	Na⁺/K⁺-ATPase	 actively	 transports	 sodium	
ions	out	of	 the	cell	and	potassium	 ions	 inside	the	cell	 to	restore	the	neuron	to	 its	 resting	potential	so	






These	 receptors	 are	 activated	 by	 glutamate,	which	 is	 an	 extracellular	 neurotransmitter	 in	 the	
brain.		During	ischemia,	through	some	proposed	mechanisms,	which	will	be	elaborated	later,	there	is	an	




the	 opening	 of	 the	 Ca2+	 channels	 there	 would	 be	 an	 increase	 in	 exocytotic	 neurotransmitter	 release	
through	normal	metabolic	pathways.		This	is	because	an	increase	in	Ca2+	in	a	cell	will	cause	an	increase	in	
cell	metabolism.	However,	due	to	the	depletion	of	ATP	in	the	cell,	this	mechanism	cannot	really	account	




The	 main	 candidate	 for	 an	 alternative	 mechanism	 is	 the	 reverse	 transport	 of	 glutamate	
transporter	 proteins.	 	 The	 transport	 of	 glutamate	 into	 the	 cell	 in	 order	 to	 prevent	 excessive	
depolarization	is	not	driven	by	ATP	but	rather	by	the	Na+	gradient	inside	the	cell	and	the	concentration	
of	K+	and	pH-changing	anions	out	of	the	cell	 (Barbour	et	al	1998).	 	When	 ischemia	occurs	and	Na⁺/K⁺-
ATPase	 begins	 to	 reduce	 in	 activity,	 the	 Na+	 gradient	 is	 decreased	 and	 the	 K+	 accumulates	 in	 the	




Normally	glutamate	 is	 taken	up	by	glia	and	converted	by	glutamine	synthetase	 into	glutamine	
and	 returned	 back	 into	 the	 neural	 soma	 (Thoreson	 and	Witkovsky,	 1999).	 	 Ischemia	 lowers	 the	 ATP	
levels	 in	 glia	 and	 causes	 a	 decrease	 in	 the	 conversion	 of	 glutamate.	 	 This	 causes	 an	 increase	 in	 the	
glutamate/glutamine	ratio,	which	may	also	lead	to	extracellular	glutamate	(Oliver	et	al,	1990).	
Once	the	cell	constantly	becomes	depolarized	excess	calcium	enters	the	cell	and	sets	off	many	
cascades	 that	 lead	 to	 cell	 death.	 Among	 the	most	 critical	 are	 free	 radical	 production	 and	 nitric	 oxide	
(NO)	synthesis,	activation	of	phospholipase	A2,	DNA	cleavage,	activation	of	proteases,	and	subsequent	

















species.	The	summed	cellular	 response	of	 these	processes,	 if	 left	unchecked,	 is	cell	death.	This	can	occur	by	the	
classical	and	rapid	necrotic	process	or	by	longer-duration	apoptosis	(Osborne	et	al.,	2004).		
Retina	Damage	in	Ischemia	
Glutamate	 is	 the	 major	 excitatory	 retinal	 neurotransmitter	 and	 is	 released	 in	 vivo,	 by	
photoreceptors,	bipolar	cells,	and	ganglion	cells.	The	photoreceptors	have	only	shown	susceptibility	to	
be	damaged	after	the	rest	of	the	retina	has	shut	down	and	studies	have	shown	that	 ischemia	has	 less	
effect	 on	 the	 outer	 layer	 of	 the	 retina	 than	 the	 inner	 layer	 of	 the	 retina	 (Peachey	 et	 al,	 1993).	 	 	 The	
reason	 that	 photoreceptors	 are	 less	 sensitive	 remains	 unknown.	 	 One	 possibility	 is	 that	 their	
mitochondria	have	a	high-density	inner	segment	and	is	maintained	on	a	smaller	pO2.		In	addition	there	is	
more	 neuroglobin	 in	 photoreceptors	 (Schmidt	 et	 al,	 2003)	 which	 helps	maintain	 oxygen	 levels	 inside	






receptors	 and	 are	 susceptible	 to	 ischemic	 attack	 through	 the	 same	mechanism.	 	 Both	 amacrine	 and	
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ganglion	 cells	 have	 many	metabotropic	 glutamate	 receptors	 which	 also	 may	 be	 the	 reason	 for	 their	
susceptibility	to	ischemic	attack	(Osborne	et	al.,	1991).	
	What	sets	ischemic	attack	on	the	retina	different	from	the	brain,	is	the	fact	that	the	retina	has	a	





Alternatively	 there	 is	a	“no	flow”	phenomenon	that	may	explain	this	difference	 (Fischer	et	al.,	












in	 ischemia	 and	 yet	 sustain	NMDA	 receptor	 functions	 in	 the	brain	 to	maintain	 cognitive	 and	memory	
processes.		
This	evidence	supports	the	idea	that	using	a	NMDA	antagonist	one	can	slow	down	or	even	stop	
ischemic	attack.	 	One	particular	 antagonist	 that	has	been	 showing	great	 results	 is	dextromethorphan.			
Dextromethorphan	is	an	antiussive	drug	and	is	used	in	over	the	counter	cough	and	cold	medicines	and	it	
has	been	shown	to	have	uses	in	pain	relief	(Bem	and	Peck,	1992).							
Evidence	 on	 retina	 health	 after	 ischemic	 attacks	 were	 obtained	 through	 Electroretinography	





restoration	 of	 blood	 flow	 than	 retina	 that	 were	 not	 treated	 with	 dextromethorphan.	 	 In	 30	 and	 60	
minute	 strokes,	 rats	 that	 were	 treated	 with	 dextromethorphan	 had	 a	 better	 recovery	 time	 and	 less	
retinal	 damage	 than	 the	 mice	 not	 treated	 with	 the	 drug	 (Cao	 et	 al.,	 1994).	 	 However,	 caution	 is	
necessary	when	studying	this	drug	because	it	may	be	that	dextromethorphan	increases	cerebral	blood	






	Dizocilpine	 (MK-801),	 another	 NMDA	 antagonist	 has	 shown	 better	 results	 in	 stopping	 retinal	
ischemia	 (Lam	 et	 al.,	 1997).	 	 However,	 it’s	 neurotoxic	 side	 affects	 causes	 reduced	 brain	 function	 and	
make	 it	 almost	 impossible	 for	 clinical	 use.	 	 Also,	 the	 lowing	 of	 ischemic	 affects	may	 be	 due	 to	 other	
metabolic	 side	 affects	 of	 MK-801	 in	 that	 it	 lowers	 CNS	 temperature,	 which	 lowers	 the	 oxygen	
consumption	during	ischemia	(Chi	et	al.,	1991).		
Other	NMDA	antagonists	have	been	used	in	studies	for	retinal	diseases.		They	include	eliprodil,	






In	 conclusion,	 ischemia	 in	 the	 retina,	 if	 left	 untreated,	 is	 almost	 certain	 to	 cause	 permanent	
damage	to	the	retina	and	eventually	to	severe	vision	 loss.	 	 Ischemia	unleashes	a	cascade	starting	with	
the	lack	of	oxygen,	which	causes	the	Na+/K+	ATPase	to	lose	function,	which	leads	to	hyper-activation	of	
glutamate	receptors.		The	lack	of	oxygen	also	leads	to	an	increase	in		 extracellular	 glutamate,	 which	
can	cause	two	forms	of	death.		Glutamate	can	lead	to	an	influx	of	ions,	which	will	be	followed	by	water	
under	osmosis	 and	 cause	 cell	 lysis.	 	Also,	 glutamate	allows	an	 increase	 in	 the	uptake	of	 calcium	 ions,	
which	activates	mechanisms	to	form	radicals	that	can	activate	apoptotic	mechanisms	in	the	cell.		
One	 proposed	 way	 of	 treating	 retinal	 ischemia	 is	 to	 administer	 non-competitive	 NMDA	









Akiyama, H., Nakazawa, T., Shimura, M., Tomita, H., & Tamai, M. (2002). Presence of mitogen-activated 
protein kinase in retinal Muller cells and its neuroprotective effect ischemia–reperfusion injury. 
Neuroreport, 13, 2103-2107. 
Attwell, D., Barbour, B., & Szatkowski, M. (1993). Nonvesicular release of neurotransmitter. Neuron., 11, 401-
407. 
Barbour, B., Brew, H., & Attwell, D. (1988). Electrogenic glutamate uptake in glial cells is activated by 
intracellular potassium. Nature, 335, 433-435. 
Barbour, B., Brew, H., & Attwell, D. (1991). Electrogenic uptake of glutamate and aspartate into glial cells 
isolated from the salamander (Ambystoma) retina. J. Physiol, 436, 169-193. 
Bem, J. L., & Peck, R. (1992). Dextromethorphan. An overview of safety issues. Drug Safe, 7, 190-199. 
Biton, B., Granger, P., Carreau, A., Depoortere, H., Scatton, B., Avenet, P. (1994). The NMDA receptor 
antagonist eliprodil (SL82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical 
neurons. Eur. J. Pharmacol. 257, 297–301. 
Bonne, C., Muller, A., & Villain, M. (1998). Free radicals in retinal ischemia. Gen. Pharmacol., 30, 275-
280. 
Brown, G. C. (1991). Systemic associations of retinal arterial obstructive disease. Int. Ophthalmol. Clin., 31, 1-14. 
Cao, W., Zaharia, M., Drumheller, A., Casanova, C., Lafond, G., Brunette, J. R., et al. (1994). Effects of 
dextromethorphan on ischemia induced electroretinogram changes in rabbit. Curr. Eye Res., (13), 97-102. 
Chan, P. H. (1996). Role of oxidants in ischemic brain damage. Stroke, 27, 1124-1129. 
Chi, O. Z., Anwar, M., Sinha, A. K., & Weiss, H. R. (1991). Effects of MK-801 on cerebral regional oxygen 
consumption in focal cerebral ischemia in rats. Circ. Res., 69, 414-420. 
David, P., Lusky, M., Teichberg, V.I., 1988. Involvement of excitatoryneurotransmitters in the damage 
produced in chick embryo retinas byanoxia and extracellular high potassium. Exp. Eye Res. 46, 
657–662. 
Digledine, R., Borges, K., D, B., & Traynelis, S. F. (1999, March). The glutamate receptor ion channels. 
Pharmacol. Rev, 51(1), 7-62. 
Doly, M., Braquet, P., Bonhomme, B., & Meyniel, G. (1984). Effects of lipid peroxidation on the isolated rat 
retina. Ophthalmic Res, 16, 292-296. 
Eby, G. A., & Eby, K. L. (2006, March). Rapid recovery from major depression using magnesium treatment. Med 
Hypotheses, 67, 362-370. 
Fischer, E. G., Ames, A. R., Hedley White, E. T., & O’Gorman, S. (1977). Reassessment of cerebral capillary 
changes in acute global ischemia and their relationship to the “no-reflow phenomenon“. Stroke, 8, 36-39. 
Fletcher, E. L., Hack, I., Brandstatter, J. H., & Wassle, H. (2000). Synaptic localization of NMDA receptor 
subunits in the rat retina. J. Comp. Neurol, 380, 98-112. 
George, C. P., Goldberg, M. P., Choi, D. W., & Steinberg, G. K. (1988). Dextromethorphan reduces neocortical 
77	
	
ischemic neuronal damage in vivo. Brain Res, 440, 375-379. 
Goto, W., Ota, T., Morikawa, N., Otori, Y., Hara, H., Kawazu, K., et al. (2002). Protective effects of timolol 
against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res, 958, 10-19. 
Hayreh, S. S., & Weingeist, T. A. (1980). Experimental occlusion of the central artery of the retina. IV: retinal 
tolerance time to acute ischaemia. Br. J. Ophthalmol, 64, 818-825. 
Kincaid, M. C., Yanoff, M., & Fine, B. S. (1998). Pathology of the eye. Duane’s Foundations of Clinical 
Ophthalmology, 6-12. 
Lam, T.T. (1997). The effect of 3-aminobenzamide, an inhibitor of poly ADP-ribose polymerase, on 
ischemia/reperfusion damage in ratretina. Res. Commun. Mol. Pathol. Pharmacol. 95, 241–252. 
Lipton, P. (1999). Ischemic cell death in brain neurons. Physiol. Rev., 79, 1431-1568. 
Lombardi, G., Moroni, F., & Moroni, F. (1994). Glutamate receptor antagonists protect against ischemia-induced 
retinal damage. Eur. J. Pharmacol., 271, 489-495. 
Mitchell, P., Smith, W., Chang, A., (1996). Prevalence and associations of retinal vein occlusion in Australia. The 
Blue Mountains Eye 
Study. Arch. Ophthalmol. 114, 1243–1247.Neal, M. J., Cunningham, J. R., Hutson, P. H., & Hogg, J. (1994). 
Effects of ischaemia on neurotransmitter release from the isolated retina. J. Neurochem, 62, 1025-1033. 
Nicoletti, F., Bruno, V., Copani, A., Casabona, G., & Knopfel, T. (1996). Metabotropic glutamate receptors: a 
new target for the therapy of neurodegenerative disorders?. Trends Neurosci, 19, 267-271. 
Nishizawa, Y. (2001). Glutamate release and neuronal damage in ischemia. Life Sci, 69, 369-381. 
Oliver, C. N., Stark-Reed, P. E., Stadtman, E. R., Liu, G. J., Carney, J. M., & Floyd, R. A. (1990). Oxidative 
damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during 
ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci, 87, 5144-5147. 
Osborne, N. N., Block, F., & Sontag, K. H. (1991). Reduction of ocular blood flow results in glial fibrillary acidic 
protein (GFAP) expression in rat retinal muller cells. Vis. Neurosci., 7, 637-639. 
Osborne, N. N., Casson, R. J., Wood, J. P., Chidlow, G., Graham, M., & Melena, J. (2004). Retinal ischemia: 
mechanisms of damage and potential therapeutic strategies. Prog. Ret. Eye Res., 23, 91-147. 
Parsons, C. G., Gruner, R., Rozental, J., Millar, J., & Lodge, D. (1993). Patch clamp studies on the kinetics and 
selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-
dimethyladamantan). Neuropharmacology, 32, 1337-1350. 
Peachey, N. S., Green, D. J., & Ripps, H. (1993). Ocular ischemia and the effects of allopurinol on functional 
recovery in the retina of the arterially perfused cat eye. Invest. Ophthalmol. Vis. Sci. , 34, 58-65. 
Schmidt, M., Giessl, A., Laufs, T., Hankeln, T., Wolfrum, U., & Burmester, T. (2003). How does the eye breathe? 
Evidence for neuroglobin-mediated oxygen supply in the mammalian retina. J Biol Chem , 278, 1932-
1935. 
Shimada, N., Graf, R., Rosner, G., & Heiss, W. D. (1993). Ischemia-induced accumulation of extracellular amino 
acids in cerebral cortex, white matter, and cerebrospinal fluid. J. Neurochem, 60, 66-71. 
78	
	
Thoreson, W. B., & Witkovsky, P. (1999). Glutamate receptors and circuits in the vertebrate retina. Prog. Retn. 
Eye Res, 18, 765-810. 
Zeevalk, G. D., & Nicklas, W. J. (1992). Evidence that the loss of the voltage-dependent Mg2+ block at the N-
methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. 
Neurochem, 59, 1211-1220. 
	
	
